跳到正文
原文
STAT Pharma 医药频道· Margaret Manto·· 23 天前AI 评分53

FDA 发布草案指南,拟简化部分个体化基因治疗审批路径

STAT+: FDA offers new details on quicker approval pathway for personalized gene therapies

AI 导读

FDA 于周二发布草案指南,拟简化部分个体化基因治疗的审批流程。罕见病倡导者此前批评 FDA 对这类疗法的处理方式,PKD Foundation 的 Paul Scribner 称该草案相当于明确表态这类疗法重要。原文为 STAT+ 付费内容,其余细节未公开。

正文

WASHINGTON – The Food and Drug Administration published draft guidance on Tuesday that would streamline approvals of some individualized gene therapies, a win for rare disease advocates who have criticized the agency’s approach to these treatments. 

“It’s sort of putting a flag in the ground and saying, ‘This is important,’” Paul Scribner, vice president of community programs and education at the PKD Foundation, said of the draft guidance at a rare disease event on Tuesday. 

Breakthroughs in gene therapies, or treatments that treat or cure diseases by altering faulty genes inside a person’s cells, have energized researchers and companies who believe many patients with rare mutations could benefit from these personalized medicines. 

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com